| Catalog No. |
Size |
Price |
Figures |
|---|
Z00013-1 mg
| 1 mg | $ 420.00 |
References:
- Wang GQ, et al. Generation of a reporter cell line for detection of infectious varicella-zoster virus and its application to antiviral studies. Antimicrob. Agents Chemother. Sep 2006; 50(9): 3142-3145.
- Sato B, et al. Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J. Virol. May 2003; 77(10): 5607-5620.
- Spengler M, et al. Interactions among structural proteins of varicella zoster virus. Arch. Virol. Suppl. 2001; (17): 71-79.
|
|---|
| Full Name | | Varicella Zoster Virus (VZV) ORF9 |
|
| Abbreviated Name-1 | VZV ORF9 |
|---|
| Description | Varicella Zoster Virus (VZV) ORF9 is an E. coli-derived recombinant. GenScript Varicella Zoster Virus (VZV) ORF9 contains the VZV ORF9 immunodominant regions. |
|---|
| Source | E. coli |
|---|
| Purity | Protein is >95% pure as determined by 10% PAGE (coomassie staining). |
|---|
| Storage | Protein is shipped at ambient temperature. Upon arrival, store at -20°C. |
|---|
| Concentration | 1 mg/ml in 25 mM Tris-HCl, 1 mM EDTA, 50% glycerol. |
|---|
| Stability | Five years frozen. One month in solution at room temperature. |
|---|
| Specificity | Immunoreactive with sera of VZV-infected individuals. |
|---|
| Applications | Antigen in ELISA and Western blots, excellent antigen for detection of VZV with minimal specificity problems. |
|---|
